ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

American Association for Cancer Research Presents Awards at 2012 Annual Meeting

April 6, 2012

In Brief: Salmon, Fidler Head ASCO, AACR; Durant, Pardee Presidents Elect; Namovicz, Other AOs Promoted

May 25, 1984

Texts Of Workshop Report Summarized

November 8, 1996

Tamoxfin Trial accrues 6,000, Problems with Minority accrual Remain

April 2, 1993

New Two-Step Matching Process Increases Success of Transplants

September 30, 2011

ACS Research Grants Hit $78.2 Million

July 18, 1986